Lilly rides Mounjaro, Zepbound to better
Time:2024-05-22 04:00:53 Source:businessViews(143)
Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Previous:'Real life' Martha from Baby Reindeer's million
Next:Tamara Ecclestone is criticised as her daughter Fifi, 10, heads out wearing heavy make
You may also like
- Hilarious moment mother asks her Cocker Spaniel to help choose her lottery numbers
- Flood, weather warnings as storm hits Australia
- Biden hosts Kishida in official visit as US, Japan bolster defense ties
- How to make sure your leftovers are safe to eat
- David Cronenberg's new grief
- Ministers announce advisory group for fast
- Titanic 'door' prop that kept Rose alive sells for more than $1m
- China's real estate giant Evergrande files for bankruptcy
- Iran helicopter crash: President Raisi, the supreme leader's protege, dies at 63